IP Library Granted Patent US 10,060,925
Granted Patent B2
US 10,060,925 · App. 14/903,956 · Granted Aug 28, 2018

Miox antibody and assay

Inventors: Joseph P. Gaut (St. Louis, MO); Jack Ladenson (St. Louis, MO); Dan Crimmins (St. Louis, MO); Vijay Modur (St. Louis, MO)
Assignee: WASHINGTON UNIVERSITY
G01N33/573C07K16/40G01N33/6893C07K2317/33C07K2317/34C07K2317/565G01N2333/90241G01N2800/347
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,060,925
App. No.
14/903,956
Granted
Aug 28, 2018
Kind
B2
Abstract

The invention relates to compositions and methods for detecting renal injury in a subject, such as proximal tubular injury associated with acute kidney injury.

Claims (17)

1. An isolated antibody, wherein the antibody specifically binds myo-inositol oxygenase (MIOX) and the heavy chain comprises the amino acid sequences of SEQ ID NOs: 4, 5, and 6, and the light chain comprises the amino acid sequences of SEQ ID NOs: 1, 2, and 3; or the heavy chain comprises the amino acid sequences of SEQ ID NOs: 10, 11, and 12, and the light chain comprises the amino acid sequences of SEQ ID NOs: 7, 8 and 9.

2. The isolated antibody of claim 1 , wherein the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO:14 and SEQ ID NO:16.

3. The isolated antibody of claim 1 , wherein the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO:13 and SEQ ID NO:15.

4. The isolated antibody of claim 1 , wherein the antibody is encoded by a nucleic acid sequence comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20.

5. The isolated antibody of claim 1 , wherein the antibody is selected from the group consisting of a single-chain antibody, an antibody fragment, a chimeric antibody, or a humanized antibody.

6. A method for measuring the amount of MIOX in a biological sample, the method comprising (i) obtaining a sample of biological fluid from a subject; and (ii) measuring the amount of MIOX in the sample by immunoassay comprising at least one isolated antibody of claim 1 .

7. The method of claim 6 , wherein the biological sample is a biological fluid selected from the group consisting of blood, plasma, serum and urine.

8. The method of claim 6 , wherein measuring the amount of MIOX in the sample by immunoassay comprises a capture antibody and a capping antibody that specifically binds MIOX.

9. The method of claim 8 , wherein the capture antibody comprises a heavy chain comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, and a light chain comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, and the capping antibody comprises a heavy chain comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, and a light chain comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9.

10. The method of claim 8 , wherein the capture antibody comprises a heavy chain comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, and a light chain comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, and the capping antibody comprises a heavy chain comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, and a light chain comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3.

11. A method for detecting renal injury in a subject, the method comprising (i) obtaining a biological sample from a subject; (ii) measuring the amount of MIOX in the sample by immunoassay using at least one isolated antibody of claim 6 ; and (iii) comparing the amount of MIOX in the sample to a reference value, wherein a greater amount of MIOX in the sample compared to the reference value indicates renal injury in the subject.

12. The method of claim 11 , wherein the renal injury is directly or indirectly associated with proximal tubular injury.

13. The method of claim 12 , wherein the proximal tubular injury is directly or indirectly associated with proximal tubular cell damage.

14. The method of claim 11 , wherein the biological sample is a biological fluid selected from the group consisting of blood, plasma, serum and urine.

15. The method of claim 11 , wherein measuring the amount of MIOX in the sample by immunoassay comprises a capture antibody and a capping antibody that specifically binds MIOX.

16. The method of claim 15 , wherein the capture antibody comprises a heavy chain comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, and a light chain comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, and the capping antibody comprises a heavy chain comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, and a light chain comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9.

17. The method of claim 15 , wherein the capture antibody comprises a heavy chain comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, and a light chain comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, and the capping antibody comprises a heavy chain comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, and a light chain comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 13, 2016
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040907/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2016
From: GAUT, JOSEPH P.; CRIMMINS, DAN; LADENSON, JACK H.; MODUR, VIJAY
To: WASHINGTON UNIVERSITY
Reel/Frame 038175/0824 →
Continuity (2)
Provisional Application 61845108 · Jul 11, 2013
Related Publication 20160216264A1 · Jul 28, 2016